KNSA Stock — Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc (KNSA)

Updated October 16, 2026.

KNSA is a Stock. Total return is 303.6% over the past 8.4 years, 85.4 points ahead of SPY at 218.2%.

Kiniksa Pharmaceuticals International is a biopharmaceutical company developing and commercializing therapies for inflammatory and autoinflammatory diseases, with a marketed product called ARCALYST for recurrent pericarditis and cardiac sarcoidosis, along with additional candidates in clinical development. The company does not currently have an established distribution schedule. This stock appeals primarily to investors seeking exposure to clinical-stage and early-commercial biopharmaceutical development rather than income.

KNSA performance versus SPY

Price and return data through 2026-10-16.

Total return is 303.6% over the past 8.4 years, 85.4 points ahead of SPY at 218.2%. Over the past year its total return — price change plus distributions reinvested — is 101.9%. Its deepest 1-year drawdown was 21.1%.

KNSA key facts

Asset type

Stock

Asset class

Equity

Inception date

05/24/2018

Distribution frequency

None

Last close

$78.59 (as of 2026-10-16)

Market cap

$3,795,053,965

Average volume

524763.0

Beta

0.036

Payout ratio

0.0%

P/E ratio

79.38

Forward P/E

59.5238

EPS

$0.99

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KNSA risks and drawbacks

The deepest 1-year drawdown on record here is 21.1%.

Who may consider KNSA — and who may not

It is a weaker fit for investors who need monthly cash flow (KNSA does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on KNSA

• All tickers starting with K

Tagged: International, Healthcare, Pharmaceutical.

Frequently asked questions